Publication Date
| In 2025 | 0 |
| Since 2024 | 0 |
| Since 2021 (last 5 years) | 0 |
| Since 2016 (last 10 years) | 0 |
| Since 2006 (last 20 years) | 2 |
Descriptor
| Behavior Modification | 2 |
| Drug Therapy | 2 |
| Pervasive Developmental… | 2 |
| Pharmacology | 2 |
| Autism | 1 |
| Behavior Disorders | 1 |
| Compliance (Psychology) | 1 |
| Familiarity | 1 |
| Genetic Disorders | 1 |
| Hyperactivity | 1 |
| Mental Retardation | 1 |
| More ▼ | |
Author
Publication Type
| Journal Articles | 2 |
| Reports - Evaluative | 1 |
| Reports - Research | 1 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewed
Direct linkArnold, L. Eugene; Aman, Michael G.; Li, Xiaobai; Butter, Eric; Humphries, Kristina; Scahill, Lawrence; Lecavalier, Luc; McDougle, Christopher J.; Swiezy, Naomi B.; Handen, Benjamin; Wilson, Krystina; Stigler, Kimberly A. – Journal of the American Academy of Child & Adolescent Psychiatry, 2012
Objective: To follow up on a three-site, 24-week randomized clinical trial (N = 124) comparing antipsychotic medication alone (MED) with antipsychotic medication plus parent training in the behavior management (COMB) of children with autism spectrum disorders and severe behavior problems. The COMB treatment had shown a significant advantage for…
Descriptors: Behavior Disorders, Familiarity, Parents, Hyperactivity
Erickson, Craig A.; Mullett, Jennifer E.; McDougle, Christopher J. – Journal of Autism and Developmental Disorders, 2009
Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). The purpose of this pilot study was to examine the effectiveness and tolerability of memantine for a number of target symptoms associated with FXS. Medical records describing open-label treatment with memantine in 6 patients with FXS and a comorbid…
Descriptors: Mental Retardation, Rating Scales, Patients, Genetic Disorders
